|
#1
27.05.2004, 16:54
|
||||
|
||||
|
valproate+ATRA against MDS
Появилась в дожурнальном варианте статья, посвященная лечению МДС вальпроевой кислотой с АТРА:
[Ссылки доступны только зарегистрированным пользователям ] Treatment of Myelodysplastic Syndromes with Valproic Acid alone or in Combination with All-Trans Retinoic Acid Andrea Kuendgen*, Corinna Strupp, Manuel Aivado, Alf Bernhardt, Barbara Hildebrandt, Rainer Haas, Ulrich Germing, and Norbert Gattermann Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany Institute of Human Genetics, Heinrich-Heine-University, Duesseldorf, Germany Valproic acid (VPA) has been shown to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in the differentiation induction of AML blasts in vitro. We treated 18 patients with myelodysplastic syndromes (MDS) and AML secondary to MDS (sAML/MDS) with VPA monotherapy (serum concentrations 50-100µg/ml). Five patients received VPA and ATRA (80mg/m2/d, d1-7, every other week). Response according to IWG criteria was observed in 8 patients (44%) on VPA monotherapy, including 1 partial remission. Median response duration was 4 months (3-9). Four of 5 patients relapsing were treated with VPA+ATRA, 2 of them responding again. Among 5 patients receiving VPA+ATRA from the start, none responded according to IWG criteria, but one patient with sAML/MDS achieved a marked reduction in peripheral and marrow blasts. Thus, VPA is of therapeutic benefit for patients with MDS, and ATRA may be effective when added later. 
|
|
|
Линейный вид
